Description: Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; Raplin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
Home Page: www.ganlee.com
No. 8, Nanfeng West 1st Street
Beijing,
101109
China
Phone:
86 10 8059 3699
Officers
| Name | Title |
|---|---|
| Mr. Gan Zhongru | Founder & Chairman |
| Mr. Cheng Sun | CFO & Deputy GM |
| Mr. Wang Bin | Deputy Gen. Mang. |
| Mr. Weiqiang Song | Deputy GM & Director |
Exchange: SHG
Country: CN
Currency: Renminbi (¥)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 119.3333 |
| Price-to-Book MRQ: | 2.0236 |
| Price-to-Sales TTM: | 8.2513 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3278 |